Eric Pauwels Sells 1,378 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels sold 1,378 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $69,037.80. Following the transaction, the chief executive officer now directly owns 85,427 shares in the company, valued at approximately $4,279,892.70. This represents a 1.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eric Pauwels also recently made the following trade(s):

• On Tuesday, January 7th, Eric Pauwels sold 1,599 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $72,498.66.

PTC Therapeutics Trading Up 0.6 %

PTCT stock opened at $50.69 on Monday. The firm has a 50 day moving average of $46.67 and a 200-day moving average of $41.62. PTC Therapeutics, Inc. has a 12-month low of $24.00 and a 12-month high of $54.16. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -8.53 and a beta of 0.62.

Institutional Investors Weigh In On PTC Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC lifted its position in shares of PTC Therapeutics by 78.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 270 shares during the period. Sterling Capital Management LLC lifted its position in shares of PTC Therapeutics by 424.4% during the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 522 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of PTC Therapeutics during the 4th quarter valued at approximately $68,000. GF Fund Management CO. LTD. acquired a new stake in shares of PTC Therapeutics during the 4th quarter valued at approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PTC Therapeutics during the 4th quarter valued at approximately $77,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Royal Bank of Canada raised their price target on PTC Therapeutics from $60.00 to $63.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. raised their price target on PTC Therapeutics from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Robert W. Baird raised their price target on PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. UBS Group raised their price target on PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Finally, Morgan Stanley raised PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $45.00 to $67.00 in a report on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, PTC Therapeutics presently has an average rating of “Hold” and an average target price of $58.85.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.